Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracellular Vesicles | 3 | 2021 | 36 | 1.830 |
Why?
|
| Melanoma | 3 | 2024 | 128 | 1.720 |
Why?
|
| Antigens, Neoplasm | 2 | 2024 | 54 | 1.640 |
Why?
|
| Wnt Signaling Pathway | 5 | 2021 | 54 | 1.360 |
Why?
|
| Serpins | 4 | 2024 | 31 | 1.320 |
Why?
|
| Fibroblasts | 2 | 2018 | 153 | 1.090 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 118 | 1.090 |
Why?
|
| Exosomes | 2 | 2017 | 92 | 1.000 |
Why?
|
| Dermatitis | 1 | 2023 | 6 | 0.870 |
Why?
|
| Arthritis | 1 | 2023 | 29 | 0.870 |
Why?
|
| Uveitis | 1 | 2023 | 23 | 0.860 |
Why?
|
| Skin | 3 | 2021 | 140 | 0.840 |
Why?
|
| Trypsin Inhibitor, Bowman-Birk Soybean | 7 | 2002 | 7 | 0.810 |
Why?
|
| Nevus | 1 | 2021 | 4 | 0.770 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 15 | 0.770 |
Why?
|
| Tubular Sweat Gland Adenomas | 1 | 2021 | 1 | 0.760 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2021 | 1 | 0.760 |
Why?
|
| Purpura | 1 | 2021 | 3 | 0.750 |
Why?
|
| Buttocks | 1 | 2021 | 6 | 0.750 |
Why?
|
| Sacrum | 1 | 2021 | 23 | 0.740 |
Why?
|
| Dermatitis, Atopic | 1 | 2018 | 2 | 0.620 |
Why?
|
| Emollients | 1 | 2018 | 2 | 0.620 |
Why?
|
| Collagen Type VII | 1 | 2018 | 1 | 0.610 |
Why?
|
| Cell Proliferation | 2 | 2021 | 774 | 0.600 |
Why?
|
| Humans | 24 | 2024 | 27119 | 0.590 |
Why?
|
| Peptides, Cyclic | 6 | 2003 | 30 | 0.570 |
Why?
|
| Dermatology | 1 | 2017 | 13 | 0.560 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 12 | 0.560 |
Why?
|
| Skin Diseases | 1 | 2017 | 28 | 0.560 |
Why?
|
| Microbiota | 1 | 2018 | 81 | 0.560 |
Why?
|
| Lymphopoiesis | 1 | 2017 | 22 | 0.550 |
Why?
|
| Wnt Proteins | 1 | 2017 | 32 | 0.550 |
Why?
|
| Nail Diseases | 1 | 2016 | 1 | 0.520 |
Why?
|
| Hemosiderin | 1 | 2016 | 2 | 0.520 |
Why?
|
| Nails | 1 | 2016 | 2 | 0.520 |
Why?
|
| Scleroderma, Systemic | 1 | 2016 | 29 | 0.510 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 447 | 0.510 |
Why?
|
| Dermatomyositis | 1 | 2016 | 60 | 0.510 |
Why?
|
| Cell Movement | 1 | 2017 | 353 | 0.500 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 277 | 0.480 |
Why?
|
| Cell Differentiation | 1 | 2017 | 398 | 0.480 |
Why?
|
| Hemorrhage | 1 | 2016 | 260 | 0.450 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 48 | 0.440 |
Why?
|
| Wound Healing | 1 | 2014 | 113 | 0.420 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2004 | 12 | 0.350 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 626 | 0.350 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 377 | 0.340 |
Why?
|
| Mice, Transgenic | 5 | 2024 | 489 | 0.320 |
Why?
|
| Chymotrypsin | 2 | 2000 | 4 | 0.310 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 367 | 0.310 |
Why?
|
| Rheumatic Diseases | 1 | 2008 | 33 | 0.290 |
Why?
|
| Infant | 2 | 2023 | 966 | 0.290 |
Why?
|
| Female | 8 | 2021 | 14635 | 0.280 |
Why?
|
| Male | 5 | 2023 | 13022 | 0.270 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 1940 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 324 | 0.260 |
Why?
|
| Adult | 4 | 2021 | 7492 | 0.250 |
Why?
|
| Aged | 3 | 2021 | 5222 | 0.250 |
Why?
|
| Threonine | 3 | 2003 | 21 | 0.250 |
Why?
|
| Protease Inhibitors | 3 | 2007 | 40 | 0.240 |
Why?
|
| Oligopeptides | 3 | 2002 | 95 | 0.240 |
Why?
|
| Pancreatic Elastase | 2 | 2007 | 8 | 0.240 |
Why?
|
| Autoantibodies | 1 | 2008 | 472 | 0.240 |
Why?
|
| Protein Conformation | 7 | 2005 | 253 | 0.230 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 1 | 0.230 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2002 | 11 | 0.230 |
Why?
|
| Trypsin | 3 | 2007 | 24 | 0.230 |
Why?
|
| Amino Acid Sequence | 8 | 2004 | 675 | 0.220 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2023 | 7 | 0.220 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 19 | 0.220 |
Why?
|
| Pruritus | 1 | 2023 | 8 | 0.220 |
Why?
|
| Granuloma | 1 | 2023 | 17 | 0.220 |
Why?
|
| Methotrexate | 1 | 2023 | 32 | 0.220 |
Why?
|
| Models, Molecular | 7 | 2007 | 445 | 0.210 |
Why?
|
| Mice | 7 | 2024 | 4473 | 0.210 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 5 | 0.210 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2023 | 3 | 0.210 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2018 | 8 | 0.210 |
Why?
|
| Immunotherapy | 1 | 2024 | 141 | 0.210 |
Why?
|
| Cells, Cultured | 2 | 2017 | 976 | 0.210 |
Why?
|
| Hydrolysis | 6 | 2007 | 58 | 0.200 |
Why?
|
| Insulin Resistance | 1 | 2024 | 172 | 0.200 |
Why?
|
| Prognosis | 1 | 2024 | 763 | 0.200 |
Why?
|
| Basement Membrane | 1 | 2021 | 6 | 0.190 |
Why?
|
| Skin Diseases, Vascular | 1 | 2021 | 3 | 0.190 |
Why?
|
| Thrombosis | 1 | 2023 | 147 | 0.190 |
Why?
|
| Calciphylaxis | 1 | 2021 | 4 | 0.190 |
Why?
|
| Fatal Outcome | 1 | 2021 | 66 | 0.180 |
Why?
|
| Complement Activation | 1 | 2021 | 25 | 0.180 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 43 | 0.180 |
Why?
|
| Incidence | 2 | 2023 | 553 | 0.180 |
Why?
|
| Bone Marrow | 1 | 2021 | 76 | 0.180 |
Why?
|
| Inpatients | 1 | 2021 | 56 | 0.180 |
Why?
|
| Animals | 9 | 2024 | 10080 | 0.180 |
Why?
|
| Mutation | 2 | 2023 | 818 | 0.180 |
Why?
|
| Biopsy | 1 | 2021 | 201 | 0.180 |
Why?
|
| Proteomics | 1 | 2021 | 177 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 247 | 0.160 |
Why?
|
| Disease Progression | 1 | 2021 | 458 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2021 | 293 | 0.160 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 18 | 0.150 |
Why?
|
| Epidermolysis Bullosa | 1 | 2018 | 2 | 0.150 |
Why?
|
| Molecular Sequence Data | 5 | 2003 | 1037 | 0.150 |
Why?
|
| Peptide Library | 4 | 2007 | 25 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 32 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2023 | 2454 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 63 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2021 | 1100 | 0.150 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 2 | 2014 | 3 | 0.150 |
Why?
|
| Binding Sites | 6 | 2004 | 341 | 0.150 |
Why?
|
| Tetraspanin 30 | 1 | 2017 | 2 | 0.150 |
Why?
|
| Wnt3A Protein | 1 | 2017 | 6 | 0.140 |
Why?
|
| Culture Media, Conditioned | 1 | 2017 | 31 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 59 | 0.140 |
Why?
|
| Kinetics | 5 | 2004 | 538 | 0.140 |
Why?
|
| Middle Aged | 2 | 2021 | 6900 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 364 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2017 | 134 | 0.130 |
Why?
|
| Bacteria | 1 | 2018 | 264 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 279 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2160 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2017 | 331 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2014 | 28 | 0.120 |
Why?
|
| beta Catenin | 1 | 2014 | 62 | 0.110 |
Why?
|
| Young Adult | 1 | 2021 | 2626 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2014 | 8 | 0.110 |
Why?
|
| Lithium | 1 | 2014 | 8 | 0.110 |
Why?
|
| Adolescent | 1 | 2021 | 2988 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 40 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 31 | 0.110 |
Why?
|
| Genes, Reporter | 1 | 2014 | 87 | 0.110 |
Why?
|
| Serine Endopeptidases | 2 | 2004 | 18 | 0.110 |
Why?
|
| Retinal Neovascularization | 1 | 2013 | 20 | 0.110 |
Why?
|
| Microcirculation | 1 | 2014 | 112 | 0.110 |
Why?
|
| Protein Binding | 3 | 2000 | 636 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 144 | 0.100 |
Why?
|
| Peptides | 3 | 2005 | 280 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 400 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 108 | 0.100 |
Why?
|
| Protein Structure, Secondary | 3 | 2001 | 130 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 766 | 0.080 |
Why?
|
| Biotin | 2 | 2000 | 25 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2008 | 18 | 0.080 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 30 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 35 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2004 | 201 | 0.070 |
Why?
|
| Nanostructures | 1 | 2008 | 62 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 508 | 0.070 |
Why?
|
| Leukocyte Elastase | 2 | 2001 | 5 | 0.050 |
Why?
|
| Models, Chemical | 2 | 2003 | 88 | 0.050 |
Why?
|
| Ulcer | 1 | 2023 | 5 | 0.050 |
Why?
|
| Weight Loss | 1 | 2024 | 72 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2023 | 15 | 0.050 |
Why?
|
| Luteinizing Hormone | 2 | 2018 | 57 | 0.050 |
Why?
|
| Cross Reactions | 2 | 2018 | 72 | 0.050 |
Why?
|
| Homeostasis | 1 | 2024 | 115 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 134 | 0.050 |
Why?
|
| Overweight | 1 | 2024 | 110 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 71 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 199 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 264 | 0.050 |
Why?
|
| Insulin | 1 | 2024 | 315 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2024 | 648 | 0.050 |
Why?
|
| Drug Stability | 1 | 2001 | 23 | 0.050 |
Why?
|
| Trypsin Inhibitors | 1 | 2001 | 1 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2001 | 30 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2000 | 17 | 0.040 |
Why?
|
| Valine | 1 | 1999 | 12 | 0.040 |
Why?
|
| Gene Library | 1 | 1999 | 45 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 1999 | 150 | 0.040 |
Why?
|
| Swine | 1 | 1999 | 221 | 0.040 |
Why?
|
| Obesity | 1 | 2024 | 654 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2018 | 75 | 0.040 |
Why?
|
| Insecta | 1 | 2018 | 24 | 0.040 |
Why?
|
| Proteins | 1 | 1999 | 245 | 0.040 |
Why?
|
| Epitopes | 1 | 2018 | 181 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 1998 | 186 | 0.030 |
Why?
|
| Disulfides | 1 | 1996 | 33 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 681 | 0.030 |
Why?
|
| Time Factors | 1 | 1999 | 1570 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2007 | 39 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 53 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 175 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 313 | 0.030 |
Why?
|
| Tryptases | 2 | 2004 | 2 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 195 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 59 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 58 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 567 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 177 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2003 | 55 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 440 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1496 | 0.020 |
Why?
|
| Retina | 1 | 2013 | 422 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Subtilisin | 1 | 2007 | 1 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2007 | 5 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2007 | 66 | 0.020 |
Why?
|
| Drug Design | 1 | 2007 | 62 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 179 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2005 | 50 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 39 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 102 | 0.010 |
Why?
|
| Immunization | 1 | 2005 | 118 | 0.010 |
Why?
|
| Antibodies | 1 | 2005 | 124 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 318 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 283 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 66 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2001 | 200 | 0.010 |
Why?
|